vs
芝商所（CME）与德康医疗（DXCM）财务数据对比。点击上方公司名可切换其他公司
芝商所的季度营收约是德康医疗的1.5倍（$1.9B vs $1.3B），德康医疗净利率更高（21.2% vs 0.1%，领先21.2%），德康医疗同比增速更快（21.6% vs 14.5%），过去两年德康医疗的营收复合增速更高（12.0% vs 10.8%）
芝商所是总部位于美国伊利诺伊州芝加哥的金融服务企业，为全球规模最大的金融衍生品交易所运营商，旗下拥有芝加哥商品交易所、芝加哥期货交易所、纽约商业交易所、纽约商品交易所等交易平台，覆盖农产品、货币、能源等品类交易，同时持有标普道琼斯指数27%的股权。
德康医疗是美国跨国医疗保健企业，专注于研发、生产及销售糖尿病管理领域的连续血糖监测（CGM）系列系统。其全球总部及研发中心位于美国加利福尼亚州圣地亚哥，生产基地分布于美国亚利桑那州梅萨、马来西亚峇都交湾及爱尔兰戈尔韦郡阿斯里。
CME vs DXCM — 直观对比
营收规模更大
CME
是对方的1.5倍
$1.3B
营收增速更快
DXCM
高出7.1%
14.5%
净利率更高
DXCM
高出21.2%
0.1%
两年增速更快
DXCM
近两年复合增速
10.8%
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $1.9B | $1.3B |
| 净利润 | $1.2M | $267.3M |
| 毛利率 | — | 62.9% |
| 营业利润率 | 0.1% | 25.6% |
| 净利率 | 0.1% | 21.2% |
| 营收同比 | 14.5% | 21.6% |
| 净利润同比 | 20.7% | 153.6% |
| 每股收益（稀释后） | — | $0.67 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CMEDXCM
| Q1 26 | $1.9B | $1.3B | ||
| Q4 25 | $1.6B | $1.3B | ||
| Q3 25 | $1.5B | $1.2B | ||
| Q2 25 | $1.7B | $1.2B | ||
| Q1 25 | $1.6B | $1.0B | ||
| Q4 24 | $1.5B | $1.1B | ||
| Q3 24 | $1.6B | $994.2M | ||
| Q2 24 | $1.5B | $1.0B |
净利润CMEDXCM
| Q1 26 | $1.2M | $267.3M | ||
| Q4 25 | $1.2B | $267.3M | ||
| Q3 25 | $908.0M | $283.8M | ||
| Q2 25 | $1.0B | $179.8M | ||
| Q1 25 | $956.2M | $105.4M | ||
| Q4 24 | $874.6M | $151.7M | ||
| Q3 24 | $912.8M | $134.6M | ||
| Q2 24 | $883.2M | $143.5M |
毛利率CMEDXCM
| Q1 26 | — | 62.9% | ||
| Q4 25 | — | 62.9% | ||
| Q3 25 | — | 60.5% | ||
| Q2 25 | — | 59.5% | ||
| Q1 25 | — | 56.9% | ||
| Q4 24 | — | 58.9% | ||
| Q3 24 | — | 59.7% | ||
| Q2 24 | — | 62.4% |
营业利润率CMEDXCM
| Q1 26 | 0.1% | 25.6% | ||
| Q4 25 | 61.8% | 25.6% | ||
| Q3 25 | 63.3% | 20.1% | ||
| Q2 25 | 66.7% | 18.4% | ||
| Q1 25 | 67.5% | 12.9% | ||
| Q4 24 | 62.1% | 17.0% | ||
| Q3 24 | 64.6% | 15.3% | ||
| Q2 24 | 65.3% | 15.7% |
净利率CMEDXCM
| Q1 26 | 0.1% | 21.2% | ||
| Q4 25 | 71.7% | 21.2% | ||
| Q3 25 | 59.1% | 23.5% | ||
| Q2 25 | 60.6% | 15.5% | ||
| Q1 25 | 58.2% | 10.2% | ||
| Q4 24 | 57.3% | 13.6% | ||
| Q3 24 | 57.6% | 13.5% | ||
| Q2 24 | 57.6% | 14.3% |
每股收益（稀释后）CMEDXCM
| Q1 26 | — | $0.67 | ||
| Q4 25 | $3.24 | $0.67 | ||
| Q3 25 | $2.49 | $0.70 | ||
| Q2 25 | $2.81 | $0.45 | ||
| Q1 25 | $2.62 | $0.27 | ||
| Q4 24 | $2.40 | $0.37 | ||
| Q3 24 | $2.50 | $0.34 | ||
| Q2 24 | $2.42 | $0.35 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $2.4B | $917.7M |
| 总债务越低越好 | $3.4B | — |
| 股东权益账面价值 | — | $2.7B |
| 总资产 | $202.0B | $6.3B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CMEDXCM
| Q1 26 | $2.4B | $917.7M | ||
| Q4 25 | $4.5B | $917.7M | ||
| Q3 25 | $2.6B | $1.8B | ||
| Q2 25 | $2.1B | $1.2B | ||
| Q1 25 | $1.5B | $904.9M | ||
| Q4 24 | $3.0B | $606.1M | ||
| Q3 24 | $2.4B | $621.2M | ||
| Q2 24 | $1.9B | $939.2M |
总债务CMEDXCM
| Q1 26 | $3.4B | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益CMEDXCM
| Q1 26 | — | $2.7B | ||
| Q4 25 | $28.7B | $2.7B | ||
| Q3 25 | $28.2B | $2.7B | ||
| Q2 25 | $27.7B | $2.6B | ||
| Q1 25 | $27.0B | $2.3B | ||
| Q4 24 | $26.5B | $2.1B | ||
| Q3 24 | $28.2B | $2.0B | ||
| Q2 24 | $27.6B | $2.4B |
总资产CMEDXCM
| Q1 26 | $202.0B | $6.3B | ||
| Q4 25 | $198.4B | $6.3B | ||
| Q3 25 | $187.1B | $7.5B | ||
| Q2 25 | $179.9B | $7.3B | ||
| Q1 25 | $157.8B | $6.8B | ||
| Q4 24 | $137.4B | $6.5B | ||
| Q3 24 | $137.8B | $6.4B | ||
| Q2 24 | $123.4B | $6.8B |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
